fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Bromazepam

All products: general benefit

Teva-Bromazepam · DIN 02230584 · 3 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Teva-Bromazepam · DIN 02230584 Manufacturer: Teva Canada Limited; listing date 1998-12-31 Health Canada: Marketed since 2015-05-29 · brand TEVA-BROMAZEPAM · ATC N05BA08 BROMAZEPAM · form Tablet · route Oral · ingredients BROMAZEPAM 3 MG · company Teva canada limited · schedule Targeted substances (cdsa iv)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Bromazepam: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0897). What the ministry pays, not the patient.

Ministry pays: $0.0897 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02230584)

Source record
DIN 02230584: Teva-Bromazepam Raw flags: sec3=Y Item: 281608123; group id 481; item number 1225; lccId None; manufacturer id TEV Source form: Tab; strength: 3mg Recorded listing: General benefit Source prices (unrounded): $0.0897; ministry $0.0897 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02230584 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49693
Interchangeable products
Apo-Bromazepam · DIN 02177161 · $0.0897 Lectopam · DIN 00518123 · not recorded
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (N05BA): coverage varies; not interchangeable

  • Alprazolam (Xanax): general benefit, not a benefit
  • Chlordiazepoxide (Librium): general benefit, not a benefit
  • Clorazepate dipotassium (Tranxene): general benefit, not a benefit
  • Diazepam (Diazepam Injection USP): general benefit, limited Use 481, not a benefit
  • Lorazepam (Apo-Lorazepam): general benefit, not a benefit
  • Oxazepam (Apo-Oxazepam): general benefit, not a benefit

1 more in the class list below

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ALPRAZOLAM

· 12 products · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 0.25mg, 0.5mg, 1mg, 2mg · Tab

CHLORDIAZEPOXIDE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 25mg · Cap

CLORAZEPATE DIPOTASSIUM

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 3.75mg, 7.5mg, 15mg · Cap

DIAZEPAM

· 10 products · Limited Use, codes 481 (1), General benefit (6), Listed, not a benefit (3) · strengths: 5mg/mL, 10mg/2mL, 15mg/3mL, 2mg, 5mg, 10mg · Inj Sol (Preservative Free), Rect Gel-2x 5mg Pk, Rect Gel-2x10mg Pk, Rect Gel-2x15mg Pk, Tab

LORAZEPAM

· 12 products · General benefit (9), Listed, not a benefit (3) · strengths: 0.5mg, 1mg, 2mg · Tab

OXAZEPAM

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 10mg, 15mg, 30mg · Tab

HYDROXYZINE HCL

· 8 products · Listed, not a benefit · strengths: 10mg, 25mg, 50mg · Cap

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-BROMAZEPAM (bromazepam) is useful for the short-term, symptomatic relief of manifestations of excessive anxiety in patients with anxiety neurosis. Geriatrics: Long-term use of APO-BROMAZEPAM should be avoided in elderly patients. Enhanced monitoring is recommended (see WARNINGS AND PRECAUTIONS, Falls and fractures; DOSAGE AND ADMINISTRATION, Dosing considerations). Pediatrics: APO-BROMAZEPAM is not recommended for children under 18 years of age (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). Page 3 of 28 https://pdf.hres.ca/dpd_pm/00067862.PDF PM date: OCT 18, 2022 Source product: APO-BROMAZEPAM; DIN 02177161; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.